This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Nurix Therapeutics’s 8K filing here.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Five stocks we like better than Nurix Therapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Battle of the Retailers: Who Comes Out on Top?
- What Are the U.K. Market Holidays? How to Invest and Trade
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What Are Dividend Challengers?
- MarketBeat Week in Review – 10/28 – 11/1
-PUNDIX.png?v=2022-10-05&h=45&w=95&zc=2){kind=small}
